JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review.
Aishwarya MuddebihalAnanta KhuranaKabir SardanaPublished in: Expert review of clinical pharmacology (2023)
The pathology of a large number of dermatological disorders is mediated via inflammatory cytokines which signal via the JAK STAT pathway. JAKinibs have shown great promise in treating cutaneous disorders refractory to conventional therapy. Their current clinical use in dermatology is based on robust evidence (for some), and anecdotal evidence for most other dermatoses.